Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 8933 results

  1. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

  2. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

  3. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

  4. Vulnerable populations: strategies for tackling inequalities

    Awaiting development Reference number: GID-QS10124 Expected publication date: TBC

  5. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

  6. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

  7. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

  8. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

  9. Abdominal aortic aneurysm

    Awaiting development Reference number: GID-QS10035 Expected publication date: TBC

  10. Acne

    Awaiting development Reference number: GID-QS10036 Expected publication date: TBC

  11. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

  12. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

  13. Diverticular disease

    Awaiting development Reference number: GID-QS10086 Expected publication date: TBC

  14. Thyroid disease

    Awaiting development Reference number: GID-QS10088 Expected publication date: TBC

  15. Primary hyperparathyroidism

    Awaiting development Reference number: GID-QS10089 Expected publication date: TBC